Ignite Creation Date:
2024-05-05 @ 11:53 PM
Last Modification Date:
2024-10-26 @ 10:41 AM
Study NCT ID:
NCT01446250
Status:
TERMINATED
Last Update Posted:
2017-01-16
First Post:
2011-09-26
Brief Title:
Alisporivir Deb025 and Boceprevir Triple Therapies in African American Participants Not Previously Treated for Chronic Hepatitis C Genotype 1
Sponsor:
Debiopharm International SA
Organization:
Debiopharm International SA
Study Overview
Official Title:
A Randomized Open Label Trial of the Safety and Efficacy of DEB025Alisporivir in Combination With Pegylated Interferon-α2a and Ribavirin Peg-INFα2aRBV and Boceprevir in Combination With Peg-INFα2aRBV in African American Treatment-naïve Patients With Chronic Hepatitis C Genotype 1
Status:
TERMINATED
Status Verified Date:
2016-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will assess the safety and efficacy of alisporivir ALV and boceprevir BOC each in combination with Peginterferon alfa-2a PEG and Ribavirin RBV in African American participants who have never received treatment for their chronic hepatitis C HCV genotype 1 infection
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None